4-(1,3-dibenzylimidazolidin-2-yl)-N,N-dimethylbenzenamine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: 4-(1,3-dibenzylimidazolidin-2-yl)-N,N-dimethylbenzenamine
• 英文别名: 4-(1,3-dibenzylimidazolidin-2-yl)-N,N-dimethylaniline
• 化学式: C₂₅H₂₉N₃
• mdl: MFCD00296276
• 分子量: 371.525
• InChiKey: PPLTZSDLFYPWIJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  28
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  9.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  N,N-双(苯基亚甲基)-1,2-乙二胺 在 sodium tetrahydroborate 作用下， 以 乙醇 、 水 为溶剂， 反应 4.0h， 生成 4-(1,3-dibenzylimidazolidin-2-yl)-N,N-dimethylbenzenamine
  参考文献：
  名称：

  Synthesis and evaluation of hexahydropyrimidines and diamines as novel hepatitis C virus inhibitors

  摘要：

  In order to identify novel anti-hepatitis C virus (HCV) agents we devised cell-based strategies and screened phenotypically small molecule chemical libraries with infectious HCV particles, and identified a hit compound (1) containing a hexahydropyrimidine (HHP) core. During our cell-based SAR study, we observed a conversion of HHP 1 into a linear diamine (6), which is the active component in inhibiting HCV and exhibited comparable antiviral activity to the cyclic HHP I. In addition, we engaged into the biological characterization of HHP and demonstrated that HHP does not interfere with HCV RNA replication, but with entry and release of viral particles. Here we report the results of the preliminary SAR and mechanism of action studies with HHP. (C) 2013 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2013.09.055

文献信息

• [EN] HEXAHYDROPYRIMIDINE, TETRAHYDRO IMIDAZOLE OR OCTAHYDROAZEPAN DERIVATIVES<br/>[FR] DÉRIVÉS HEXAHYDROPYRIMIDINE, TÉTRAHYDROIMIDAZOLE OU OCTAHYDROAZÉPANE
  申请人：ACTAR AB

  公开号：WO2007139492A1

  公开（公告）日：2007-12-06

  [EN] A compound of formula (I) R2 R3 1 R R4 N N R5 n (I) for use as a medicament. The medicament is suitable for the treatment of conditions such as cancer, keloids and granulomatous skin disorders, psoriasis, pathological neovascularization, excessive hair growth and excessive body weight and for inhibition of stem cell proliferation and induction of differentiation after spinal cord injury and CNS diseases. A method of treat- ing a mammal by administration of a compound of formula (I).
  [FR] La présente invention concerne un composé répondant à la formule (I) R2 R3 1 R R4 N N R5 n (I) destiné à une utilisation comme médicament. Le médicament est approprié pour le traitement d'affections telles que le cancer, des chéloïdes et des troubles granulomateux cutanés, le psoriasis, la néovascularisation pathologique, une pilosité excessive et un poids corporel excessif et pour l'inhibition de la prolifération de cellules souches et l'induction de la différentiation après une lésion médullaire et des troubles du SNC. La présente invention concerne également un procédé de traitement d'un mammifère par l'administration d'un composé répondant à la formule (I).
• Synthesis and evaluation of hexahydropyrimidines and diamines as novel hepatitis C virus inhibitors
  作者：Jong Yeon Hwang、Hee-Young Kim、Suyeon Jo、Eunjung Park、Jihyun Choi、Sunju Kong、Dong-Sik Park、Ja Myung Heo、Jong Seok Lee、Yoonae Ko、Inhee Choi、Jonathan Cechetto、Jaeseung Kim、Jinhwa Lee、Zaesung No、Marc Peter Windisch

  DOI：10.1016/j.ejmech.2013.09.055

  日期：2013.12

  In order to identify novel anti-hepatitis C virus (HCV) agents we devised cell-based strategies and screened phenotypically small molecule chemical libraries with infectious HCV particles, and identified a hit compound (1) containing a hexahydropyrimidine (HHP) core. During our cell-based SAR study, we observed a conversion of HHP 1 into a linear diamine (6), which is the active component in inhibiting HCV and exhibited comparable antiviral activity to the cyclic HHP I. In addition, we engaged into the biological characterization of HHP and demonstrated that HHP does not interfere with HCV RNA replication, but with entry and release of viral particles. Here we report the results of the preliminary SAR and mechanism of action studies with HHP. (C) 2013 Elsevier Masson SAS. All rights reserved.